CDC logoSafer Healthier People CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

Skip navigation links Search NIOSH  |  NIOSH Home  |  NIOSH Topics  |  Site Index  |  Databases and Information Resources  |  NIOSH Products  |  Contact Us

NIOSH Program Portfolio

 

Manufacturing

NORA Manufacturing Sector Strategic Goals

9277409 - Criteria Document Update: Chromium (VI)

Start Date: 10/1/2000
End Date: 9/30/2012

Principal Investigator (PI)
Name: Kathleen Macmahon
Phone: 513-533-8547
E-mail: kqm1@cdc.gov
Organization: NIOSH
Sub-Unit: EID
Funded By: NIOSH

Primary Goal Addressed
6.0

Secondary Goal Addressed
None


Attributed to Manufacturing
100%

Project Description

Short Summary

This NIOSH criteria document update on hexavalent chromium (Cr(VI)) will provide current information on its health effects and recommendations for protection from exposure to Cr(VI) in the workplace. This document will include a critical analysis of Cr(VI) lung cancer epidemiology, exposure assessment studies, animal studies, and risk assessments. This document will clarify the NIOSH policy on the Recommended Exposure Limits for all forms of Cr(VI).





Description

This criteria document update will provide information and guidance to the occupational health community as well as users of hexavalent chromium (Cr(VI)). Potential adverse health effects of Cr(VI) exposure include dermatitis, respiratory irritation, and lung cancer. Data has demonstrated that soluble Cr(VI) compounds, previously reported to be non-carcinogenic, may be carcinogenic. This document will provide an evaluation of the current health data available and will provide updated Recommended Exposure Limits (RELs) for all Cr(VI) compounds. A NIOSH criteria document update on Cr(VI) will be published to provide current information to manufacturers, distributors, handlers, and end-users on the health effects of Cr(VI) compounds. The document will include a critical analysis of recent information on current Cr(VI) epidemiology and exposure assessment studies, animal studies, and risk assessments. It will include a thorough review of recent information on the carcinogenicity of soluble Cr(VI) compounds which at the time of the NIOSH 1975 criteria document were considered to be non-carcinogenic. This project translates research into practice for safety and health professionals, employers, and workers.



In FY04, the Cr(VI) topic page was posted to the NIOSH Website and the risk assessment completed.

In FY05, the first draft of the document was produced.

In FY06, internal review occurred.

In FY08, the external review draft was prepared.

In FY09, external review will occur.



All OMB data quality requirements will be met in FY09. Comments will be addressed throughout FY09 and a final document will be prepared for transmittal to the NIOSH OD in late FY09 to early FY10.



Objectives

The objectives of this project are to provide updated information and guidance to the occupational health community as well as users of Cr(VI) to reduce occupational exposure to Cr(VI). This project will provide recommendations to employers and employees to reduce occupational exposure to Cr(VI). This project will update NIOSH policies regarding occupational exposure to Cr(VI) and provide input to the OSHA.



Mission Relevance

More than 550,000 workers are exposed to hexavalent chromium (Cr(VI)) in the United States. Cr(VI) exposure has been associated with irritant and allergic dermatitis, respiratory irritation, and lung cancer. The 1975 NIOSH Cr(VI) criteria document recommended two different recommended exposure limits (RELs) dependent on the solubility of the Cr(VI) compound. The NIOSH 1988 testimony on the Occupational Safety and Health Administration (OSHA) proposed rule on air contaminants stated that new data seemed to support classification of both soluble and insoluble Cr(VI) compounds as 'potential occupational carcinogens' under the OSHA carcinogen policy. This updated criteria document will analyze the current health data available on Cr(VI) and clarify the NIOSH policy on the RELs for Cr(VI) compounds. This research to practice project will produce communication products supporting the NIOSH mission to assure a safe and healthful workplace. This project also supports the following goals:



Sector Programs

S09PPMNFSG6

Strategic Goal 6: Reduce the prevalence of cancer due to exposures in the manufacturing sector.



Cross Sector Health Outcome Programs

Immune and Dermal Diseases

09PPDRMSG1

Dermal Strategic Goal 1: Contribute to the reduction of occupational skin disease.

Dermal Activity/Output Goal 1.1.2 (09PPDRMAOG1.1.2): Identify and recommend effective methods of risk communication and management to decision makers, employers and workers on dermal hazards in the workplace and provide information to improve exposure controls.



Other Cross Sector Programs

Authoritative Recommendation Development

09PPAURSG1

Strategic Goal 1: Reduce and prevent occupational injuries, illnesses, and fatalities by supporting NORA sector and cross-sector programs in the development of authoritative recommendations.



Page last updated: June 3, 2011
Page last reviewed: May 23, 2011
Content Source: National Institute for Occupational Safety and Health (NIOSH) Office of the Director

 

NIOSH Program:

Manufacturing